Roche/Trimeris Fuzeon Discontinuation Rate Is One Factor In Poor Sales
This article was originally published in The Pink Sheet Daily
Executive Summary
Sales of the HIV agent remain disappointing at $35.9 mil. worldwide for 2003. Roche says it remains convinced Fuzeon can reach peak targets – just not as quickly as it hoped.